Mesabi Trust’s decision to cut its distribution, after receiving lower royalty payments from Cleveland-Cliffs (CLF), has drawn fresh attention to uncertainties around the miner’s Northshore iron ore operations and the related industry risks. See our latest analysis for Cleveland-Cliffs. Despite the Mesabi news, Cleveland-Cliffs' recent share price moves have been mixed, with a 1-month share price return of 12.20% and a 90-day share price return showing a 32.45% decline, while the 1-year total...

The Australian stock market is experiencing a period of optimism, with the ASX 200 futures seeing a significant rise as global equities receive a boost from renewed geopolitical negotiations. Amidst this fluctuating landscape, identifying stocks that are trading below their fair value can offer potential opportunities for investors looking to capitalize on market inefficiencies.

Mesoblast Limited ( ASX:MSB ) shareholders (or potential shareholders) will be happy to see that insider Gregory George...

Mesoblast recently announced that the US FDA has granted Investigational New Drug clearance to move directly into a registrational clinical trial of Ryoncil in children with Duchenne muscular dystrophy, enrolling 76 patients aged 5 to 9 with time-to-stand at nine months as the primary endpoint. This trial positions Mesoblast to apply its first-in-class mesenchymal stromal cell therapy, already approved for pediatric steroid-refractory acute graft-versus-host disease, to a new high-need...

If you are wondering whether Mesoblast at around A$2.02 is still priced attractively or already reflecting high expectations, the valuation story matters more than ever. The share price has seen mixed returns, with a 27.1% decline year to date and a 25.9% gain over the last year, while the three year return of 112.0% contrasts with a 6.6% decline over five years. Recent coverage of Mesoblast has focused on its position within the pharmaceuticals and biotech space and how sentiment around its...

The Australian market is experiencing a dip amid geopolitical tensions, with investors closely monitoring the impact of supply disruptions and regional conflicts on indices and commodities like oil and gold. In such uncertain times, growth companies with high insider ownership can be particularly appealing as they often reflect strong management confidence and alignment with shareholder interests, making them worthy of attention despite broader market challenges.

Amidst a cautious atmosphere on the ASX, driven by geopolitical uncertainties, Australian shares have seen modest gains. In such a climate, investors often look beyond established giants to explore opportunities in lesser-known sectors. Penny stocks, while an older term, continue to represent smaller or newer companies with potential for growth and value; focusing on those with solid financials can uncover promising investment opportunities.

Key Insights Using the 2 Stage Free Cash Flow to Equity, MSB Global Group Berhad fair value estimate is RM0.16 MSB...

NEW YORK (AP) — Mesabi Trust (MSB) on Friday reported net income of $2.8 million in its fiscal third quarter. The New York-based company said it had profit of 21 cents per share. The iron ore miner posted revenue of $3.6 million in the period.

NEW YORK (AP) — Mesabi Trust (MSB) on Monday reported profit of $4.7 million in its fiscal second quarter. On a per-share basis, the New York-based company said it had profit of 36 cents. The iron ore miner posted revenue of $5.6 million in the period.